Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.28M Sell
3,624
-47
-1% -$16.8K 0.28% 91
2025
Q4
$1.2M Buy
3,671
+193
+6% +$61.2K 0.27% 94
2025
Q3
$982K Sell
3,478
-263
-7% -$76.3K 0.23% 107
2025
Q2
$1.04M Sell
3,741
-244
-6% -$69.1K 0.22% 112
2025
Q1
$1.24M Sell
3,985
-1,016
-20% -$300K 0.27% 102
2024
Q4
$1.3M Sell
5,001
-296
-6% -$87.8K 0.28% 96
2024
Q3
$1.71M Sell
5,297
-7
-0.1% -$2.29K 0.37% 75
2024
Q2
$1.66M Buy
5,304
+393
+8% +$115K 0.38% 69
2024
Q1
$1.4M Buy
4,911
+3,037
+162% +$889K 0.34% 84
2023
Q4
$540K Sell
1,874
-200
-10% -$54.5K 0.15% 152
2023
Q3
$557K Buy
2,074
+707
+52% +$176K 0.17% 145
2023
Q2
$303K Buy
1,367
+277
+25% +$64.3K 0.09% 197
2023
Q1
$263K Buy
1,090
+320
+42% +$78.6K 0.09% 199
2022
Q4
$202K Buy
+770
New +$206K 0.09% 197
2022
Q2
Sell
-733
Closed -$177K 208
2022
Q1
$177K Buy
+733
New +$168K 0.06% 211
2021
Q4
Sell
-732
Closed -$155K 216
2021
Q3
$155K Buy
+732
New +$168K 0.06% 228

Other funds holding AMGN

Herold Advisors's AMGN Position: Q1 2026 in Review

Herold Advisors reduced its Amgen (AMGN) stake by 1.3% in Q1 2026, selling an estimated $16.8K and leaving 3,624 shares worth $1.28M. The position accounts for 0.28% of the portfolio, ranked #91.

Herold Advisors first reported a position in AMGN in Q3 2021 and has held it in 16 quarters since. The position peaked at $1.71M in Q3 2024. 3,126 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Herold Advisors held 3,624 shares of Amgen worth $1.28M as of Q1 2026.
  • Herold Advisors sold 47 Amgen shares in Q1 2026, an estimated $16.8K.
  • Amgen made up 0.28% of Herold Advisors's portfolio in Q1 2026, its #91 holding.
  • Herold Advisors first reported a position in Amgen in Q3 2021 and has held it in 16 quarters since.
  • Herold Advisors's Amgen position peaked at $1.71M in Q3 2024.
  • 3,126 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Herold Advisors's 13F filing for Q1 2026, filed 15 May 2026.